DE69222950D1 - Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten - Google Patents

Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten

Info

Publication number
DE69222950D1
DE69222950D1 DE69222950T DE69222950T DE69222950D1 DE 69222950 D1 DE69222950 D1 DE 69222950D1 DE 69222950 T DE69222950 T DE 69222950T DE 69222950 T DE69222950 T DE 69222950T DE 69222950 D1 DE69222950 D1 DE 69222950D1
Authority
DE
Germany
Prior art keywords
pellel
adminisible
products containing
containing acid
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69222950T
Other languages
English (en)
Other versions
DE69222950T2 (de
Inventor
Dong Min
Kee Um
Yong Kim
Pyeong Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Discovery Co Ltd
Original Assignee
Sunkyung Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunkyung Industries Ltd filed Critical Sunkyung Industries Ltd
Application granted granted Critical
Publication of DE69222950D1 publication Critical patent/DE69222950D1/de
Publication of DE69222950T2 publication Critical patent/DE69222950T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
DE69222950T 1991-12-31 1992-12-30 Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten Expired - Lifetime DE69222950T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR910025847 1991-12-31
PCT/KR1992/000083 WO1993013138A1 (en) 1991-12-31 1992-12-30 A method for preparing enteric-coated oral drugs containing acid-unstable compounds

Publications (2)

Publication Number Publication Date
DE69222950D1 true DE69222950D1 (de) 1997-12-04
DE69222950T2 DE69222950T2 (de) 1998-05-28

Family

ID=19327322

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69222950T Expired - Lifetime DE69222950T2 (de) 1991-12-31 1992-12-30 Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten

Country Status (15)

Country Link
US (1) US5399700A (de)
EP (1) EP0619825B1 (de)
JP (1) JP2662518B2 (de)
KR (1) KR960008231B1 (de)
CN (1) CN1033790C (de)
BR (1) BR9207000A (de)
CA (1) CA2127111C (de)
DE (1) DE69222950T2 (de)
EG (1) EG20115A (de)
ES (1) ES2111148T3 (de)
HU (1) HU217135B (de)
MX (1) MX9207676A (de)
RU (1) RU2105773C1 (de)
TW (1) TW224049B (de)
WO (1) WO1993013138A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
AU745707B2 (en) * 1995-09-21 2002-03-28 Pharma Pass Llc novel composition containing an acid-labile omeprazole and process for its preparation
AU6998796A (en) * 1995-09-21 1997-04-28 Pharma Pass Llc Novel composition containing an acid-labile benzimidazole and process for its preparation
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
NZ337592A (en) * 1997-03-13 2001-01-26 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100281521B1 (ko) * 1998-03-31 2001-02-15 김종인 프라바스타틴나트륨이 함유된 약제 조성물
US6733778B1 (en) * 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
DE69913197T2 (de) * 1998-12-18 2004-09-02 Abbott Laboratories, Abbott Park Natriumhydrogendivalproat-formulierungen mit gesteuerter freigabe
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
GB2376231A (en) * 2001-06-06 2002-12-11 Cipla Ltd Benzimidazole-cyclodextrin inclusion complex
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
US20050171057A1 (en) * 2002-01-15 2005-08-04 Altana Pharma Ag Pantoprazole cyclodextrin inclusion complexes
EP1469839A2 (de) * 2002-01-25 2004-10-27 Santarus, Inc. Transmukosale verabreichung von protonenpumpeninhibitoren
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
US20070060556A1 (en) * 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
KR100473422B1 (ko) * 2003-06-12 2005-03-14 박원봉 렉틴 함유 천연물의 장용성 코팅용 조성물
US8993599B2 (en) * 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
KR20050105565A (ko) * 2004-04-30 2005-11-04 에스케이케미칼주식회사 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) * 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MX2007008141A (es) * 2005-01-03 2007-12-10 Lupin Ltd Composicion farmaceutica de sustancias labiles en medio acido.
CA2654402A1 (en) * 2006-06-01 2007-12-06 Adel Penhasi Multiple unit pharmaceutical formulation
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
ITMI20121264A1 (it) * 2012-07-19 2014-01-20 Recordati Ind Chimica E Farma Ceutica S P A Forma farmaceutica gastro-resistente a rilascio ritardato
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260536C3 (de) * 1972-12-11 1975-07-10 Fa. H. Trommsdorff, 5100 Aachen MolekiileinschluBverbindungen aus einem Silberalkanolammin-Komplex und beta-Cycloheptaamylose, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3427787A1 (de) * 1984-07-27 1986-01-30 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Wirkstoffkomplexe von 5-methoxy-2((4-methoxy-3,5-dimethyl-2-pyridyl) methylsulfinyl)-1h-benzimidazol mit cyclodextrinen, deren herstellung und arzneimittel
US5053240A (en) * 1989-10-24 1991-10-01 Kalamazoo Holdings, Inc. Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides

Also Published As

Publication number Publication date
MX9207676A (es) 1993-06-01
CN1076124A (zh) 1993-09-15
ES2111148T3 (es) 1998-03-01
TW224049B (de) 1994-05-21
KR960008231B1 (ko) 1996-06-21
EG20115A (en) 1997-07-31
EP0619825B1 (de) 1997-10-29
CA2127111C (en) 1996-05-21
DE69222950T2 (de) 1998-05-28
CA2127111A1 (en) 1993-07-08
HU9401666D0 (en) 1994-09-28
KR930012016A (ko) 1993-07-20
EP0619825A1 (de) 1994-10-19
HU217135B (hu) 1999-11-29
JP2662518B2 (ja) 1997-10-15
WO1993013138A1 (en) 1993-07-08
RU2105773C1 (ru) 1998-02-27
BR9207000A (pt) 1995-11-28
HUT70494A (en) 1995-10-30
JPH07506088A (ja) 1995-07-06
CN1033790C (zh) 1997-01-15
US5399700A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
DE69222950T2 (de) Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten
IL100899A0 (en) Beta-amino-alpha-hydroxycarboxylic acid derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
IL107221A0 (en) Carboxylic acid derivatives, pharmaceutical compositions containing them and processes for their preparation
FI935513A (fi) Karboksyylihappojohdannaiset, näitä sistältävät lääkeaineet ja menetelmä niiden valmistamiseksi
DE3676248D1 (de) Ubidecarenon enthaltende arzneimittel.
IL103126A (en) 5-amino-4-hydroxyhexanoic acid derivatives, process for their preparation and pharmaceutical compositions containing them
EP0420459A3 (en) Oral pharmaceutical composition for acid sensitive proteinaceous agents
ZA905861B (en) Pharmaceutical composition for oral administration containing nac
ITMI921123A0 (it) Formulazioni farmaceutiche orali contenenti antocianosidi
IL101771A0 (en) Carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them
IL103293A0 (en) Substituted imidazolyl-propenoic acid derivatives,their preparation and pharmaceutical compositions containing them
DE3579000D1 (de) Imidazolylalkylguanidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
AT397797B (de) Capsaicin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
IL103058A0 (en) Bicyclic carboxylic acid derivatives,their manufacture and pharmaceutical compositions containing them
IL102362A0 (en) 4-amino-3-hydroxycarboxylic acid derivatives,their production and pharmaceutical compositions containing them
DE3865908D1 (de) Ibuprofen enthaltendes pharmazeutisches mittel.
HU9203866D0 (en) Method for producing benzoic acid derivatives and pharmaceutical preparatives containing said compounds
DE69104608D1 (de) Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
PT81409B (de) 1,3,4-thiadiazolderivate verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69302279T2 (de) 3-und 5-substituierte 1,2,3,4,-oxatriazol-5-imin derivate, verfahren zu deren herstellung, diese enthaltende arzneimittel und verwendung dieser verbindungen zur herstellung von arzneimitteln
DE3676097D1 (de) 15(r)-5-fluorprostazykline und diese verbindungen enthaltende arzneimittel.
DE3889327D1 (de) Platinkomplexe enthaltende arzneimittel.
AT389304B (de) Neue aminoalkanoyl-dibenzo (d,g) (1,3,6)dioxazocinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
PH25927A (en) 3,4-dihydroisoquinolinylacetic acid derivatives and pharmaceutical composition containing these compounds
ATE73662T1 (de) Diphosphonsaeurederivat enthaltendes arzneimittel zur oralen gabe.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R071 Expiry of right

Ref document number: 619825

Country of ref document: EP